Decreased miR-320 expression is associated with breast cancer progression, cell migration, and invasiveness via targeting Aquaporin 1. (12th March 2018)

• Record Type: Journal Article
• Authors: Luo, Liang; Yang, Rui; Zhao, Shaojie; Chen, Yu; Hong, Shanchao; Wang, Ke; Wang, Tiejun; Cheng, Jing; Zhang, Ting; Chen, Daozhen
• Is Part Of: Acta biochimica et biophysica Sinica. Volume 50:Number 5(2018:May)
• Page Start: 473
• Page End: 480
• Publication Date: 2018-03-12
• Subjects: miR-320 -- AQP1 -- breast cancer -- prognosis -- cell migration -- invasiveness; Biochemistry -- Periodicals; Biophysics -- Periodicals; 572.05
• DOI: 10.1093/abbs/gmy023
• Languages: English
• ISSNs: 1672-9145

Abstract

Abstract: Our previous studies have demonstrated that Aquaporin 1 (AQP1) is overexpressed in breast cancer. However, the mechanism remains elusive. MicroRNA 320 (miR-320) downregulation has been reported in various types of cancers, and it may regulate AQP1 expression. In this study, miR-320 and AQP1 expressions were investigated by quantitative reverse transcription-PCR, in situ hybridization, and immunohistochemistry. The clinicopathological implications of these molecules were also analyzed. We found that miR-320 expression is downregulated in both plasma and tumor tissue in human breast cancer patients. Survival analysis showed that reduced expression of miR-320 and overexpression of AQP1 are associated with worse prognosis. Luciferase assays showed that miR-320 negatively regulates AQP1 expression. In addition, cell proliferation, migration, and invasion assays were performed to investigate the effects of miR-320 on breast cancer cells. Our results showed that miR-320 overexpression inhibits cell proliferation, migration, and invasion in breast cancer cells by downregulating AQP1. These observations suggested that miR-320 downregulation may enhance AQP1 expression in breast cancer, favoring tumor progression. Our findings indicated that miR-320 and AQP1 may serve as prognostic biomarkers and therapeutic targets in the treatment of breast cancer.